Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR EXON 19 DELETION ( ENST00000275493.7 )
EGFR EXON 19 DELETION ( ENST00000275493.7 )
Associated Disease
lung adenocarcinoma
Source Database
CIViC Evidence
Description
In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively). This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/983
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/133
Rating
4
Evidence Type
Predictive
Disease
Lung Adenocarcinoma
Evidence Direction
Supports
Drug
Afatinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
25589191
Drugs
Drug NameSensitivitySupported
AfatinibSensitivitytrue